Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Eli Lilly reported full results from its phase 2 SYNERGY-MASH trial of GLP-1 and GIP agonist tirzepatide – already on the market as Mounjaro for diabetes and Zepbound for obesity – in biopsy ...

Where will Eli Lilly be in five years? Despite Lilly's huge success in treating diabetes and obesity, it's not the leader in those markets. That honor belongs to Novo Nordisk ( NVO 1.36%), which sells ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Topline results from the BMT-801 Phase 2 trial, released last month, demonstrated statistically significant weight loss with bremelanotide co-administered with tirzepatide versus placebo over an 8 ...

New data documented dramatic shifts in prescribing for both type 2 diabetes (T2D) and weight loss, particularly with the uptake of tirzepatide (Lilly ... progressing into phase 3 trials and ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Lilly's Mounjaro and Zepbound, which share the same generic drug (tirzepatide ... drug in phase 2 clinical studies as a potential treatment for metabolic-associated steatohepatitis (MASH ...